After AdCom rejection, FDA rebuffs Novo Nordisk’s once-weekly insulin
The company did not expect to resolve concerns related to manufacturing and the safety profile for type 1 diabetes by the end of the year.
The company did not expect to resolve concerns related to manufacturing and the safety profile for type 1 diabetes by the end of the year.
What's Your Reaction?
